Skip to main content
Journal cover image

Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.

Publication ,  Journal Article
Hu, R; Wei, W; Mian, A; Gonter-Aubin, K; Kabel, C; Mato, A; Stephens, DM; Hanlon, A; Khajavian, S; Shadman, M; Brander, D; Madanat, Y ...
Published in: Eur J Haematol
May 2022

INTRODUCTION: Frontline treatment of hairy cell leukemia (HCL) with a single course of the purine nucleoside analog (PNA) produces a high rate of complete remission (CR) with prolonged durations. At the time of relapse, although treatment guidelines recommend re-treatment with a PNA alone or in combination with rituximab (R), practice patterns vary and data supporting each approach are limited. METHODS: We conducted a multisite outcomes analysis of patients treated for HCL between 1995 and 2018 at six US medical centers. All patients were treated with frontline PNA and subsequently required treatment with a PNA alone (PNA) or with R (+R). RESULTS: Of the 88 patients analyzed, 56 (63.6%) received second-line PNA and 22 (36.4%) received a PNA + R. Baseline characteristics of both groups were similar. There was no difference in median PFS [67 months (95% CI 43.8 non-reached (NR)) vs. 65 months (95% CI 60-NR)] or 5-year OS [98% (95% CI 0.94-1) vs. 94% (95% CI 0.83-1), p = .104] in the PNA versus PNA + R cohorts, respectively. CONCLUSION: To our knowledge, this is the largest study evaluating the role of R in treatment of relapsed HCL and suggests that there is no advantage to the addition of R to PNA therapy at the time of first re-treatment.

Duke Scholars

Published In

Eur J Haematol

DOI

EISSN

1600-0609

Publication Date

May 2022

Volume

108

Issue

5

Start / End Page

379 / 382

Location

England

Related Subject Headings

  • Treatment Outcome
  • Rituximab
  • Recurrence
  • Purines
  • Purine Nucleosides
  • Nucleosides
  • Leukemia, Hairy Cell
  • Immunology
  • Humans
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hu, R., Wei, W., Mian, A., Gonter-Aubin, K., Kabel, C., Mato, A., … Hill, B. T. (2022). Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. Eur J Haematol, 108(5), 379–382. https://doi.org/10.1111/ejh.13744
Hu, Rachel, Wei Wei, Agrima Mian, Kristen Gonter-Aubin, Charlene Kabel, Anthony Mato, Deborah M. Stephens, et al. “Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.Eur J Haematol 108, no. 5 (May 2022): 379–82. https://doi.org/10.1111/ejh.13744.
Hu R, Wei W, Mian A, Gonter-Aubin K, Kabel C, Mato A, et al. Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. Eur J Haematol. 2022 May;108(5):379–82.
Hu, Rachel, et al. “Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.Eur J Haematol, vol. 108, no. 5, May 2022, pp. 379–82. Pubmed, doi:10.1111/ejh.13744.
Hu R, Wei W, Mian A, Gonter-Aubin K, Kabel C, Mato A, Stephens DM, Hanlon A, Khajavian S, Shadman M, Brander D, Madanat Y, Park JH, Tallman M, Pinilla-Ibarz J, Hill BT. Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. Eur J Haematol. 2022 May;108(5):379–382.
Journal cover image

Published In

Eur J Haematol

DOI

EISSN

1600-0609

Publication Date

May 2022

Volume

108

Issue

5

Start / End Page

379 / 382

Location

England

Related Subject Headings

  • Treatment Outcome
  • Rituximab
  • Recurrence
  • Purines
  • Purine Nucleosides
  • Nucleosides
  • Leukemia, Hairy Cell
  • Immunology
  • Humans
  • 1102 Cardiorespiratory Medicine and Haematology